aMAP评分是中期肝细胞癌的独立风险因素:一项大型回顾性队列研究

Yaying Chen1, Yanhong Shi1, Linbin Lu1

  • 1Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.

Journal of Cancer
|June 7, 2023
PubMed
概括

年龄-男性-白蛋白-白血球-血小板 (aMAP) 评分预测了中期肝细胞癌 (HCC) 的生存率. 这种新型的诺米图改善了HCC患者的预后准确性.